Based on the fact that Nav1.6 GoF results in severe epileptic phenotypes, two Nav1.6 inhibitors have also been shown to improve the phenotype in another zebrafish model of Dravet syndrome with Nav1.1 haploinsufficiency (Weuring et al., 2020). Here, SCN1A is linked to encephalopathy, progressive, early-onset, with brain edema and/or leukoencephalopathy.